<DOC>
	<DOCNO>NCT02742766</DOCNO>
	<brief_summary>This study phase I , randomize , placebo-controlled , double-blind ( sponsor unblind ) , three part study . The primary objective study characterize safety , tolerability GSK3008356 single dose , 14 daily repeat dose healthy subject 28 daily repeat dose obese subject . The study three part . Part 1 , single multiple-dose , dose-rising study healthy subject . Part 2 , 14-day , repeat-dose , dose-rising study healthy subject , part 3 28-day , repeat-dose study obese subject . For Parts 1 2 , data prior dos cohort available prior escalation decision . Data Parts 1 2 available prior initiation three parallel cohort Part 3 . A dose escalation meeting hold review data document decision proceed plan make alteration dose , indicate . Part 1 , Part 2 Part 3 study approximately 88 , 24 30 subject , respectively .</brief_summary>
	<brief_title>Safety , Tolerability Preliminary Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Single Repeat Oral Doses GSK3008356 Healthy Obese Subjects</brief_title>
	<detailed_description />
	<criteria>Between 18 65 year age inclusive , time signing informed consent . For Part 1 Part 2 : Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . For Part 3 : Obese subject may chronic disease specifically exclude require chronic medication treatment otherwise healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) For Part 1 Part 2 body mass index ( BMI ) 1925 kilogram per meter square ( inclusive ) For Part 3 BMI &gt; =30 kilogram per meter square Males Females nonchildbearing potential follow : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication least five halflives study medication last dose study medication . 1 . Vasectomy documentation azoospermia . 2 . Male condom plus partner use one follow contraceptive option : Contraceptive subdermal implant ; Intrauterine device intrauterine system ; Oral Contraceptive , either combined progestogen alone ; Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch Males Females nonchildbearing potential follow : A female subject eligible participate pregnant ( confirm negative serum human chorionic gonadotrophin [ hCG ] test ) , lactate , follow condition applies : Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( MlU/ml ) estradiol &lt; 40 picograms ( pg ) per ml ( &lt; 147 picomoles per liter ( pmol/L ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt allow . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 time upper limit normal ( isolated bilirubin &gt; 1.5 time upper limit normal acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) QTcF &gt; 450 millisecond ( msec ) Current chronic history gastrointestinal illness condition interfere normal gastrointestinal anatomy motility . Examples include gastrointestinal bypass surgery , cholecystectomy , partial total gastrectomy , small bowel resection , vagotomy , malabsorption , Crohn 's disease , ulcerative colitis , irritable bowel syndrome ( IBS ) , celiac sprue . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study drug , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . By exception , subject may take acetaminophen ( &lt; =2 gram per day ) 48 hour prior first dose study drug . Subjects refrain consumption red wine , Seville oranges , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication final dose . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 standard drink . One standard drink equivalent 10 gram alcohol : 285 milliliter ( mL ) beer , 100 mL wine 30 mL 40 % alcohol volume distil spirit . For Part 1 Part 2 , urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . For potent immunosuppressive agent , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 750 mL within 90 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dose escalation study</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GSK3008356</keyword>
	<keyword>Tolerability</keyword>
</DOC>